Parkinson's disease patients converted from an oral skin patch dopamine agonist therapy is safe and effective
Wisconsin researchers recently in 119 Parkinson's disease patients in the observed change from oral dopamine agonist rotigotine skin patch treatment efficacy. Results A total of 114 people successfully completed the conversion of treatment, which previously taking Requip (ropinirole), pramipexole (pramipexole) or cabergoline (cabergoline) of the patients were 46, 47 and 21. rotigotine skin patch dose is mainly based on the conversion of dopamine agonist oral dose to determine. If patients taking Requip 2mg or 0.5mg or 0.8mg pramipexole cabergoline are generally converted into the active drug containing 2mg of rotigotine skin patch. It was found that conversion therapy in patients with Parkinson's disease symptoms and did not increase, on the contrary, UPDRS score overall improvement also appeared previously taking ropinirole, pramipexole or cabergoline treatment in patients after a conversion months, UPDRS score decreased by 0.8,2.1 and 3.1 points. Patients are generally better tolerated.
The researchers believe that Parkinson's disease patients converted from oral dopamine agonist skin patch treatment is very safe and effective.
Parkinson's disease patients converted from an oral skin patch dopamine agonist therapy is safe and effective
ReplyDeleteWisconsin researchers recently in 119 Parkinson's disease patients in the observed change from oral dopamine agonist rotigotine skin patch treatment efficacy. Results A total of 114 people successfully completed the conversion of treatment, which previously taking Requip (ropinirole), pramipexole (pramipexole) or cabergoline (cabergoline) of the patients were 46, 47 and 21. rotigotine skin patch dose is mainly based on the conversion of dopamine agonist oral dose to determine. If patients taking Requip 2mg or 0.5mg or 0.8mg pramipexole cabergoline are generally converted into the active drug containing 2mg of rotigotine skin patch. It was found that conversion therapy in patients with Parkinson's disease symptoms and did not increase, on the contrary, UPDRS score overall improvement also appeared previously taking ropinirole, pramipexole or cabergoline treatment in patients after a conversion months, UPDRS score decreased by 0.8,2.1 and 3.1 points. Patients are generally better tolerated.
The researchers believe that Parkinson's disease patients converted from oral dopamine agonist skin patch treatment is very safe and effective.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Lenalidomide
AZD1152-HQPA
ZM-447439
Tozasertib
PHA-680632
MLN8054
JNJ-7706621
CYC-116
CCT 137690
Alisertib